Strategic Collaboration with Khalifa University

Creo and Khalifa University establish a Strategic Research Collaboration to capitalise on Creo's Intellectual Property (IP) estate alongside Khalifa University's research expertise

Creo Medical and internationally highly-ranked Khalifa University of Science and Technology in Abu Dhabi, have established a strategic collaboration to explore innovative commercial opportunities, with an initial focus on healthcare challenges relevant to the population in the United Arab Emirates (UAE), and the wider Middle East and North Africa region using the resources and expertise available at Khalifa University in Abu Dhabi to capitalise on Creo's Intellectual Property (IP) estate.

Having recently performed first procedures in the UAE, Creo will also leverage the collaboration to support its regional distributors and core clinical operations, including the development of clinical research with key customers in Abu Dhabi and the wider region.

This collaboration is aligned with Khalifa University's strategic objective to enhance enterprise targeted research with highly innovative partners. Khalifa University's deep tech initiative encompasses research partnerships but also investments in start-ups, incubation services, a science and technology park, an endowment fund, and a continuing education programme. This collaboration is also in line with the UAE Government's policy and helps further Khalifa University's ambition to become one of the world's premier research institutions.

Craig Gulliford, Chief Executive Officer of Creo Medical, said:

Creo has broad and deep IP that underpins its Kamaptive Electrosurgical Advanced Energy and Non-Thermal Plasma Sterilisation technology used in current products as well as offering significant potential for future products and treatments. As part of our strategy, we are driven to exploit our IP either directly or in partnership with third-parties, as shown by our Robotic Assisted Surgery collaborations. Khalifa University is a research-intensive organisation with a similar drive to develop and commercially exploit leading technologies, at scale and on a global basis. The combination of Creo's people, technology and IP with Khalifa University's teams, technologies, facilities and resources represents a great opportunity for both organisations to advance and commercialise incremental technology and products and enhance research profiles internationally."

Professor Sir John O'Reilly, President, Khalifa University, said:

"We are delighted to enter into this strategic collaboration with Creo that marks a significant milestone in our ongoing efforts to advance medical science, technology and innovation, seeing it taken through to commercialisation and application to the benefit of patients. Such a collaboration between an internationally highly-ranked university and Creo, a leader in medical device technology, bears testament to our shared commitment to obtaining healthcare solutions relevant to UAE and globally. By combining Creo's groundbreaking intellectual property and Khalifa University's extensive research capabilities and resources, we are poised to explore new opportunities and develop impactful solutions to healthcare challenges."

Posted 05/02/2024

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)

Read

13 May 2024

Directorate Changes - May 2024

Read

07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation

Read

02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital

Read

24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings

Read

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read